The present research work deals with the development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Aceclofenac and Drotaverin HCl in bulk and formulation. Chromatographic separation was achieved on ODS HG-5 RP C 18 (250 X 4.6 mm, 5 µm) using the mobile phase consisting of Acetonitrile and1% triethylamine (TEA) in the ratio of 90:10 pH 2.16 adjusted with Ortho phosphoric acid. The mobile phase was pumped at a flow rate of 1.0 mL/min and UV detection was observed at 224 nm. The retention time was found to be 3.57 min for Aceclofenac and 6.15 min for Drotaverin HCl. The linearity concentrations are obtained from in the range of 30-70 µg/ml for Aceclofenac and 24-56 µg/ml for Drotaverin HCl respectively with correlation coefficient was 0.999 and 0.998. The proposed method was found to be simple, accurate, precise and reproducible and developed method can be suggest to routine quality control analysis for simultaneous estimation of Aceclofenac and Drotaverin HCl in pharmaceutical dosage forms.
INTRODUCTION
Aceclofenac chemically known as 2-[ [2-[2-[(2, 6-dichlorophenyl) amino] phenyl] acetyl] oxy] acetic acid. It is a largely based on the inhibition of prostaglandin synthesis. Aceclofenac is a potent inhibitor of the enzyme cyclooxygenase, which is involved in the production of prostaglandins. It inhibits synthesis of the inflammatory cytokines interleukin (IL)-1 and tumor necrosis factor and prostaglandin E2 (PGE2) production (Budavari,1997) .
Fig 1: Structure of Aceclofenac
Drotaverin HCl chemically known as (1Z)-1-[ (3,4-diethoxyphenyl) methylidene]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline.It is a selective inhibitor of phosphodiesterase 4, and has no anticholinergic effects. Drotaverin has been shown to possess dosedependent analgesic effects in animal models. One small study has shown drotaverin to be eliminated mainly non-renally (Mahajan VK et al, 2006) . form by using UV (Jameelunnisa B and Abdul R , 2008) and RP-HPLC (Bolaji O et al, 1993 ) ( Rasagna A et al, 2014) 
Preparation of standard solution
About 100 mg of Aceclofenac and 60 mg of Drotaverin HCl were weighed and transferred into a 100 mL volumetric flask containing 25 mL of water. The solution was stirred for 5 minutes and made up with a further quantity of the mobile phase to get 0.1mg/mL and 0.5 mg/mL Aceclofenac and Drotaverin HCl respectively. This solution was further diluted to get required concentrations during study.
Preparation of Sample Solution:
Aceclofenac and Drotaverin. HCl combined dosage form was purchased from the Local market. 20 tablet are individually weighed and powdered. Drug equivalent to 10 mg of Aceclofenac and Drotaverin tablet powder transferred into 10 ml volumetric flask dissolved in 7 ml of mobile phase . The contents of the flask were sonicated for about 20 min for complete solubility of the drug and the volume was made up to 10 mL with mobile phase. Then the mixture was filtered through 0.45μ membrane filter. The mean peak areas of the drugs were calculated and the drug content in the formulation was calculated. 
Specificity
The system suitability for specificity was carried out to determine whether there is any interference of any impurities in retention time of analytical peak.
The study was performed under Different conditions 
System suitability:
The system performance parameters obtained from system suitability test were found to be within limits for Drotaverin HCl &Aceclofenac indicated that the developed method is precise. The results were shown in table 3 .
Linearity
The data obtained in the calibration studies when subjected to linear-regression analysis showed a linear relationship between peak areas and concentrations in the range of 24-56 µg/ml for Drotaverin and 30-70µg/ml for Aceclofenac. The linearity of calibration graphs and adherence of the system to Beer's law was validated by high value of correlation coefficient. The data of regression analysis and calibration curve were shown in Table 4 and Figure 4 &5.
Accuracy
The recoveries obtained were indicating that the method was accurate. Commonly used formulation excipients were subjected to chromatographic analysis and it was observed that there was no interfering peak at the retention time of Drotaverin.HCl& Aceclofenac. 
Robustness:
The robustness of the method was assessed by assaying test solutions under different analytical conditions deliberately changed from the original conditions. For each different analytical condition the standard solution and test solution were prepared separately. The result obtained from assay of the test solution was not affected by varying the conditions and was in accordance with the true value. System suitability data were also found to be satisfactory during variation of the analytical conditions. The analytical method therefore remained unaffected by slight but deliberate changes in the analytical conditions. The results obtained for selected factors remained unaffected by small variations of these parameters indicated that the method was robust.
Flow variation:
Robustness of test method was demonstrated by injecting system suitability and test preparation under normal condition (i.e. as such condition) and each of the altered conditions mentioned below Condition: Change in flow rate to 1.0± 0.1 mL
RESULTS AND DISCUSSION
Linearity: Correlation coefficient of the linearity study was found to R 2 =0.998 and 0.999 with linear regression equation Y=46573X+5706 for Drotaverin and Y=161434X-32034 for Aceclofenac, which proves the method was linear.
Accuracy: As the recovery results are found between 98.0% to 102.0%, the study proves that the method is accurate for the estimation.
Precision:
The %RSD of areas from six preparations precision level should not be more than 2.0%. 
CONCLUSION
A simple, precise, robust and cost effective stability indicting RP-HPLC method has been developed & validated for the analysis of Drotaverine and Aceclofenac API. Based on peak purity results, obtained from the analysis of samples using described method, it can be concluded that the absence of co-eluting peak along with the main peak of Drotaverine & Aceclofenac indicated that the developed method is specific for the estimation of Drotaverine &Aceclofenac. Further the proposed RP-HPLC method has excellent sensitivity, precision and reproducibility. Even though no attempt has been made to identify the degraded products proposed method can be used as a stability indicating method for assay of Drotaverine and Aceclofenac in commercial formulations.
